Scientific guidelines with summary-of-product-characteristics recommendations
Submitted by Anonymous (not verified) on 27 November 2024 - 12:30
Scientific guidelines with summary-of-product-characteristics recommendations
List of medicinal products under additional monitoring
Submitted by Anonymous (not verified) on 27 November 2024 - 11:00
List of medicinal products under additional monitoring
List of medicinal products under additional monitoring
Submitted by Anonymous (not verified) on 27 November 2024 - 11:00
List of medicinal products under additional monitoring
The role of members representing patients' and healthcare professionals' organisations on EMA scientific committees
Submitted by Anonymous (not verified) on 27 November 2024 - 10:45
The role of members representing patients' and healthcare professionals' organisations on EMA scientific committees
Human medicines European public assessment report (EPAR): Vaniqa, eflornithine, Date of authorisation: 19/03/2001, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 27 November 2024 - 9:18
Human medicines European public assessment report (EPAR): Vaniqa, eflornithine, Date of authorisation: 19/03/2001, Revision: 24, Status: Authorised
Minutes of the PRAC meeting on 30 September - 03 October 2024
Submitted by Anonymous (not verified) on 27 November 2024 - 8:54
Minutes of the PRAC meeting on 30 September - 03 October 2024
Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Date of authorisation: 20/09/2007, Revision: 42, Status: Authorised
Submitted by Anonymous (not verified) on 26 November 2024 - 16:22
Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Date of authorisation: 20/09/2007, Revision: 42, Status: Authorised
List of medicines currently in PRIME scheme
Submitted by Anonymous (not verified) on 26 November 2024 - 11:27
List of medicines currently in PRIME scheme
LinkedIn Live session: Improving efficiency of approval process for new medicines in the EU , Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 December 2024, 12:30 (CET) to 5 December 2024, 13:30 (CET)
Submitted by Anonymous (not verified) on 26 November 2024 - 10:59
LinkedIn Live session: Improving efficiency of approval process for new medicines in the EU , Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 December 2024, 12:30 (CET) to 5 December 2024, 13:30 (CET)
Thirteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 November 2024, 09:00 (CET) to 22 November 2024, 14:00 (CET)
Submitted by Anonymous (not verified) on 25 November 2024 - 16:15
Thirteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 November 2024, 09:00 (CET) to 22 November 2024, 14:00 (CET)